Aquestive Therapeutics initiated with an Outperform at JMP Securities. JMP Securities analyst Jason Butler initiated Aquestive Therapeutics with an Outperform rating and $29 price target, stating that the benefits of its core oral-film-based delivery technology has been validated through multiple successful partnerships and the company is now leveraging it on an internal pipeline of drug candidates. He believes FDA approvals for wholly owned candidates including Libervant and Sympazan are likely over the next 12-18 months, Butler tells investors.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.